Trump’s Takeover of the Republican Party
Readers discuss a column by David Brooks. Also: Tears for [...]
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
The pharmaceutical company will give up its ownership rights to [...]
Un esperanzador experimento de ultrasonido para los tratamientos del cerebro
Algunos fármacos para tratar enfermedades como el alzhéimer o el [...]
An Ultrasound Experiment Tackles a Giant Problem in Brain Medicine
The effects of drugs that treat Alzheimer’s, cancer and other [...]
FDA Approves, Leqembi, New Treatment for Early Alzheimer’s
The drug, Leqembi, may modestly slow cognitive decline in early [...]
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The report said the F.D.A.’s approval process for Aduhelm was [...]
What A.L.S. and Alzheimer’s Drug Approvals Have in Common
Regulators must balance patient’s needs with their safety.
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage [...]
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, [...]
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious [...]